SCHEMBL7613680

SCHEMBL7613680

CC(CCc1ncccc1P(=O)(O)Cc1ccccc1)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.38
TSHR P16473 2/20 0.37
KMT2A Q03164 1/20 0.36
TBXAS1 P24557 2/20 0.36
LMNA P02545 1/20 0.36
KDM4E B2RXH2 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPT P10636 1/20 0.34
ANPEP P15144 1/20 0.34
ERAP2 Q6P179 1/20 0.34
ERAP1 Q9NZ08 1/20 0.34
KCNA5 P22460 1/20 0.34
LAP3 P28838 1/20 0.34
APAF1 O14727 1/20 0.34
LTB4R Q15722 1/20 0.34
CYSLTR2 Q9NS75 1/20 0.34
CYSLTR1 Q9Y271 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7614446 0.78 TBXAS1 (0.40) TSHRKMT2ATBXAS1LMNASMN1; SMN2
SCHEMBL7609311 0.78 KMT2A (0.36) ATMTSHRKMT2ASMN1; SMN2CYP1A2
SCHEMBL7608846 0.75 CYSLTR2 (0.39) TSHRKMT2ASMN1; SMN2CYP1A2ANPEP
SCHEMBL7607672 0.73 LMNA (0.36) KMT2ALMNAKDM4ESMN1; SMN2
SCHEMBL5134277 0.73 TSHR (0.43) TSHRKMT2ASMN1; SMN2ANPEPERAP2
SCHEMBL29201831 0.72 KDM4E (0.46) ATMTSHRKMT2ATBXAS1LMNA
SCHEMBL30716136 0.72 KDM4E (0.46) ATMTSHRKMT2ATBXAS1LMNA
SCHEMBL264775 0.69 TSHR (0.68) TSHRKMT2ASMN1; SMN2LTB4R
SCHEMBL12670558 0.69 TSHR (0.68) TSHRKMT2ASMN1; SMN2LTB4R
SCHEMBL1073143 0.69 TSHR (0.68) TSHRKMT2ASMN1; SMN2LTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020151503-A1 Methods of cancer treatment using naaladase inhibitors SLUSHER BARBARA S (US) 2002-10-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151503-A1 Methods of cancer treatment using naaladase inhibitors NAALAD2, DNPEP, ACP3 ATM 1426/4885TSHR 4252/4885KMT2A 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.